Valvular Heart Disease Interventional Trials From 2000 to 2024
VHD trials have expanded in scale and scope with increased trial-level mean age. However, persistent sex disparities and demographic variability highlight the need for more inclusive trial designs to guide equitable valve therapy.
Authors
- Chieh-Mei Tsai (ORCID: https://orcid.org/0000-0002-8052-6664)
- Christine Lin (ORCID: https://orcid.org/0000-0001-6470-2712)
- Nathan Ross B. Bantayan (ORCID: https://orcid.org/0000-0001-9088-8880)
- John Vincent Magalong (ORCID: https://orcid.org/0000-0002-2276-0647)
- Frederick Berro Rivera (ORCID: https://orcid.org/0000-0001-9100-0724)
- Mayra Guerrero (ORCID: https://orcid.org/0000-0002-9151-8096)
- Mandeep Singh (ORCID: https://orcid.org/0000-0002-9750-746X)
- Abdullah Al‐Abcha (ORCID: https://orcid.org/0000-0002-9025-7453)
- Gabriel A Tangco
- Polyn Luz S Pine
- Nicole Ann Tesoro
Institutions
- New York City Health and Hospitals Corporation (US)
- Rush University Medical Center (US)
- Mayo Clinic (US)
- Princess Royal University Hospital (GB)
- Yeovil District Hospital NHS Foundation Trust (GB)
- San Beda University (PH)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- JACC Advances
- Published
- 2025-11-29
- DOI
- https://doi.org/10.1016/j.jacadv.2025.102384
- Citations
- 1
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39